Accuracy of Self-Reported Screening Mammography Use: Examining Recall among Female Relatives from the Ontario Site of the Breast Cancer Family Registry
Evidence of the accuracy of self-reported mammography use among women with familial breast cancer risk is limited. This study examined the accuracy of self-reported screening mammography dates in a cohort of 1,114 female relatives of breast cancer cases, aged 26 to 73 from the Ontario site of the Breast Cancer Family Registry. Self-reported dates were compared to dates abstracted from imaging reports. Associations between inaccurate recall and subject characteristics were assessed using multinomial regression. Almost all women (95.2% at baseline, 98.5% at year 1, 99.8% at year 2) accurately reported their mammogram use within the previous 12 months. Women at low familial risk (OR = 1.77, 95% CI: 1.00–3.13), who reported 1 or fewer annual visits to a health professional (OR = 1.97, 95% CI: 1.15, 3.39), exhibited a lower perceived breast cancer risk (OR = 1.90, 95% CI: 1.15, 3.15), and reported a mammogram date more than 12 months previous (OR = 5.22, 95% CI: 3.10, 8.80), were significantly more likely to inaccurately recall their mammogram date. Women with varying levels of familial risk are accurate reporters of their mammogram use. These results present the first evidence of self-reported mammography recall accuracy among women with varying levels of familial risk. 1. Introduction Having a family history of breast cancer has been established as one of the most important risk factors for the development of breast cancer [1–3]. A reduction in breast cancer mortality attributable to mammography among women aged 50 to 74 has been demonstrated [4–6]. In Canada, average-risk women aged 50 to 74 are recommended to undergo screening mammography every 2 to 3 years [7]. In Ontario, mammography is available to women aged 50 to 74 through the Ontario Breast Screening Program (OBSP), and with physician referral through imaging facilities outside of the screening program [8]. Screening guidelines for high-risk women, based on expert opinion, typically include annual mammography and/or MRI starting at age 40 or 10 years prior to the earliest age of onset observed in the family, or as young as age 25 for BRCA mutation carriers [9–15]. In 2011, the OBSP was expanded to include annual combined MRI and mammography screening for women aged 30 to 69 considered to be at very high risk of breast cancer (i.e., BRCA1/2 mutation carriers or family history suggestive of hereditary breast cancer) (Cancer Care Ontario, Internal Communication, 2011). Self-reported data is often used in epidemiologic research evaluating the use of cancer screening. The validity of self-reported
References
[1]
Collaborative Group on Hormonal Factors in Breast Cancer, “Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease,” Lancet, vol. 358, no. 9291, pp. 1389–1399, 2001.
[2]
P. D. Pharoah, N. E. Day, S. Duffy, D. F. Easton, and B. A. Ponder, “Family history and the risk of breast cancer: a systematic review and meta-analysis,” International Journal of Cancer, vol. 71, no. 5, pp. 800–809, 1997.
[3]
M. Bevier, K. Sundquist, and K. Hemminki, “Risk of breast cancer in families of multiple affected women and men,” Breast Cancer Research and Treatment, vol. 132, no. 2, pp. 723–728, 2012.
[4]
L. L. Humphrey, M. Helfand, B. K. S. Chan, and S. H. Woolf, “Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 137, no. 5, part 1, pp. 347–360, 2002.
[5]
H. D. Nelson, K. Tyne, A. Naik, C. Bougatsos, B. K. Chan, and L. Humphrey, “Screening for breast cancer: an update for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 151, no. 10, pp. 727–737, 2009.
[6]
K. Kerlikowske, D. Grady, S. M. Rubin, C. Sandrock, and V. L. Ernster, “Efficacy of screening mammography: a meta-analysis,” Journal of the American Medical Association, vol. 273, no. 2, pp. 149–154, 1995.
[7]
Canadian Task Force on Preventive Health Care, M. Tonelli, S. Connor Gorber et al., “Recommendations on screening for breast cancer in average-risk women aged 40–74 years,” Canadian Medical Association Journal, vol. 183, no. 17, pp. 1991–2001, 2011.
[8]
A. M. Chiarelli, E. Halapy, V. Nadalin, R. Shumak, F. O'Malley, and V. Mai, “Performance measures from 10 years of breast screening in the Ontario Breast Screening Program, 1990/91 to 2000,” European Journal of Cancer Prevention, vol. 15, no. 1, pp. 34–42, 2006.
[9]
D. G. R. Evans and F. Lalloo, “Risk assessment and management of high risk familial breast cancer,” Journal of Medical Genetics, vol. 39, no. 12, pp. 865–871, 2002.
[10]
D. M. Eccles, D. G. R. Evans, and J. Mackay, “Guidelines for a genetic risk based approach to advising women with a family history of breast cancer,” Journal of Medical Genetics, vol. 37, no. 3, pp. 203–209, 2000.
[11]
F. Eisinger, N. Alby, A. Bremond et al., “Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee,” Annals of Oncology, vol. 9, no. 9, pp. 939–950, 1998.
[12]
P. M？ller, G. Evans, N. Haites et al., “Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on inherited breast cancer,” Disease Markers, vol. 15, no. 1–3, pp. 207–211, 1999.
[13]
E. Warner, R. E. Heisey, V. Goel, J. C. Carroll, and D. R. McCready, “Hereditary breast cancer: risk assessment of patients with a family history of breast cancer,” Canadian Family Physician, vol. 45, pp. 104–112, 1999.
[14]
P. L. Chart and E. Franssen, “Management of women at increased risk for breast cancer: preliminary results from a new program,” Canadian Medical Association Journal, vol. 157, no. 9, pp. 1235–1242, 1997.
[15]
D. Horsman, B. J. Wilson, D. Avard et al., “Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation,” Journal of Obstetrics and Gynaecology Canada, vol. 29, no. 1, pp. 45–60, 2007.
[16]
S. A. Newell, A. Girgis, R. W. Sanson-Fisher, and N. J. Savolainen, “The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review,” American Journal of Preventive Medicine, vol. 17, no. 3, pp. 211–229, 1999.
[17]
G. H. Rauscher, T. P. Johnson, I. C. Young, and J. A. Walk, “Accuracy of self-reported cancer-screening histories: a meta-analysis,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 4, pp. 748–757, 2008.
[18]
M. Howard, G. Agarwal, and A. Lytwyn, “Accuracy of self-reports of Pap and mammography screening compared to medical record: a meta-analysis,” Cancer Causes and Control, vol. 20, no. 1, pp. 1–13, 2009.
[19]
E. D. Paskett, C. M. Tatum, D. W. Mack, H. Hoen, L. D. Case, and R. Velez, “Validation of self-reported breast and cervical cancer screening tests among low-income minority women,” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 9, pp. 721–726, 1996.
[20]
L. S. Caplan, M. T. Mandelson, and L. A. Anderson, “Validity of self-reported mammography: examining recall and covariates among older women in a health maintenance organization,” American Journal of Epidemiology, vol. 157, no. 3, pp. 267–272, 2003.
[21]
P. G. McGovern, N. Lurie, K. L. Margolis, and J. S. Slater, “Accuracy of self-report of mammography and Pap smear in a low-income urban population,” American Journal of Preventive Medicine, vol. 14, no. 3, pp. 201–208, 1998.
[22]
N. P. Gordon, R. A. Hiatt, and D. I. Lampert, “Concordance of self-reported data and medical record audit for six cancer screening procedures,” Journal of the National Cancer Institute, vol. 85, no. 7, pp. 566–570, 1993.
[23]
D. Degnan, R. Harris, J. Ranney, D. Quade, J. A. Earp, and J. Gonzalez, “Measuring the use of mammography: two methods compared,” American Journal of Public Health, vol. 82, no. 10, pp. 1386–1388, 1992.
[24]
S. Sudman and N. M. Bradburn, “Effects of time and memory factors on response in surveys,” Journal of the American Statistical Association, vol. 68, no. 344, pp. 805–815, 1973.
[25]
A. Pijpe, R. L. Mulder, P. Manders, F. E. van Leeuwen, and M. A. Rookus, “Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers,” Journal of Clinical Epidemiology, vol. 64, no. 12, pp. 1434–1443, 2011.
[26]
G. Larouche, K. Bouchard, J. Chiquette, C. Desbiens, J. Simard, and M. Dorval, “Self-reported mammography use following BRCA1/2 genetic testing may be overestimated,” Familial Cancer, vol. 11, no. 1, pp. 27–32, 2012.
[27]
J. A. Knight, H. J. Sutherland, G. Glendon, N. F. Boyd, and I. L. Andrulis, “Characteristics associated with participation at various stages at the Ontario site of the Cooperative Family Registry for Breast Cancer Studies,” Annals of Epidemiology, vol. 12, no. 1, pp. 27–33, 2002.
[28]
E. M. John, J. L. Hopper, J. C. Beck et al., “The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer,” Breast Cancer Research, vol. 6, no. 4, pp. R375–389, 2004.
[29]
A. M. Chiarelli, L. D. Marrett, and G. A. Darlington, “Pregnancy outcomes in females after treatment for childhood cancer,” Epidemiology, vol. 11, no. 2, pp. 161–166, 2000.
[30]
L. R. Zhang, A. M. Chiarelli, G. Glendon et al., “Influence of perceived breast cancer risk on screening behaviors of female relatives from the Ontario site of the Breast Cancer Family Registry,” European Journal of Cancer Prevention, vol. 20, no. 4, pp. 255–262, 2011.
[31]
M. A. Campitelli, A. M. Chiarelli, L. Mirea et al., “Adherence to breast and ovarian cancer screening recommendations for female relatives from the Ontario site of the Breast Cancer Family Registry,” European Journal of Cancer Prevention, vol. 20, no. 6, pp. 492–500, 2011.
[32]
C. Balleyguier, S. Ayadi, K. van Nguyen, D. Vanel, C. Dromain, and R. Sigal, “BIRADS classification in mammography,” European Journal of Radiology, vol. 61, no. 2, pp. 192–194, 2007.
[33]
L. Cortesi, D. Turchetti, I. Marchi et al., “Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience,” BMC Cancer, vol. 6, article 210, 2006.
[34]
I. M. Lipkus, B. K. Rimer, and T. S. Strigo, “Relationships among objective and subjective risk for breast cancer and mammography stages of change,” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 12, pp. 1005–1011, 1996.
[35]
D. A. Binder, “On the variances of asymptotically normal estimators from complex surveys,” International Statistical Review, vol. 51, pp. 279–292, 1983.
[36]
J. G. Morel, “Logistic regression under complex survey designs,” Survey Methodol, vol. 15, pp. 203–223, 1989.
[37]
K. Armstrong, J. A. Long, and J. A. Shea, “Measuring adherence to mammography screening recommendations among low-income women,” Preventive Medicine, vol. 38, no. 6, pp. 754–760, 2004.
[38]
V. L. Champion, U. Menon, D. H. McQuillen, and C. Scott, “Validity of self-reported mammography in low-income African-American women,” American Journal of Preventive Medicine, vol. 14, no. 2, pp. 111–117, 1998.
[39]
L. Suarez, D. A. Goldman, and N. S. Weiss, “Validity of Pap smear and mammogram self-reports in a low-income Hispanic population,” American Journal of Preventive Medicine, vol. 11, no. 2, pp. 94–98, 1995.
[40]
O. Baron-Epel, N. Friedman, and O. Lernau, “Validity of self-reported mammography in a multicultural population in Israel,” Preventive Medicine, vol. 46, no. 6, pp. 489–491, 2008.
